A Phase 2 interventional study of TAK-041 and Placebo in Stable Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 15th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 3rd registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in Bulgaria, Romania, United Kingdom
Ages 18–55
Neurocrine Biosciences · Sites in United States, Puerto Rico, Serbia
Ages 18–65
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Bulgaria, Hungary and 2 more countries
Ages 18–65
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico and 2 more countries
Ages 18–65
By country, each count listing its studies:
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2017.
This study's enrollment of 23 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 88 studies on the registry; 18 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Schizophrenia by Neurocrine Biosciences that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963034Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-10 |
| NCT07105098Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-11 |
| NCT07288333Neurocrine BiosciencesEvaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.
The drug being tested in this study is called TAK-041. TAK-041 is being tested to treat people who have stable schizophrenia. This study will look whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved in people who take TAK-041 in addition to standard care.
The study will enroll approximately 32 patients. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment sequences -which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) to receive either TAK-041 40 mg or Placebo first and then will be crossed over to receive the opposite Intervention.
All participants will be asked to take oral suspension on Day 1 of each Period. There will be a wash-out Period of 35 days between the dosing days in Period 1 and 2.
This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately 126 to 154 days. Participants will make multiple visits to the clinic plus a final visit 77 days after receiving their last dose of drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)
TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)
TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)
TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)
TAK-041 suspension
TAK-041 placebo-matching suspension
Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration
BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.
Time frame: Baseline (Day -1) and Day 14
Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration
Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.
Time frame: Day 1
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as: alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN), alkaline phosphatase \>3.0 U/L\*ULN, aspartate aminotransferase \>3.0 U/L\*ULN, bilirubin \>34.2 umol/L\*ULN, calcium \<1.75 mmol/L, \>2.88 mmol/L, chloride \<75 mmol/L, \>126 mmol/L, creatinine \>177umol/L, gamma glutamyl transferase \>3 U/L\*ULN, glucose \<2.8 mmol/L, \>19.4 mmol/L, potassium\<3 mmol/L, \>6 mmol/L, sodium \<130 mmol/L, \>150 mmol/L,Urea \<130 mmol/L, erythrocytes \<0.8\*LLN \>1.2\*ULN, hematocrit \<0.8\*LLN, \>1.2\*ULN, hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN, leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN, platelets \<75(10\^9/L), \>600(10\^9/L).
Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements At Least Once Post Dose
Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure were measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C.
Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Post Dose
The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec).
Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
Treatment-emergent suicidal ideation (SI) or suicidal behavior (SB) compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
Time frame: Baseline (Day -1) and Days 14, 35 and 77
Participants took part in the study at single investigative sites in United Kingdom from 21 December 2017 to 06 November 2019.
| Milestone | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics |
|---|---|---|---|---|
| Started | 3 | 4 | 9 | 7 |
| Completed | 3 | 4 | 9 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics |
|---|---|---|---|---|
| Started | 3 | 4 | 9 | 7 |
| Completed | 3 | 4 | 9 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics |
|---|---|---|---|---|
| Started | 3 | 4 | 9 | 7 |
| Treated | 2 | 4 | 8 | 6 |
| Completed | 2 | 4 | 8 | 6 |
| Not completed | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 1 |
BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.
| t-scale | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| Baseline | 29.72 ± 12.867 | 27.35 ± 12.753 | 27.89 ± 8.214 |
| Day 14 | 2.28 ± 6.963 | 5.35 ± 6.944 | 1.31 ± 5.618 |
Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.
| BOLD signal | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration | 0.23 ± 0.396 | 0.23 ± 0.202 | 0.03 ± 0.458 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) | 57.1 | 71.4 | 53.3 |
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as: alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN), alkaline phosphatase \>3.0 U/L\*ULN, aspartate aminotransferase \>3.0 U/L\*ULN, bilirubin \>34.2 umol/L\*ULN, calcium \<1.75 mmol/L, \>2.88 mmol/L, chloride \<75 mmol/L, \>126 mmol/L, creatinine \>177umol/L, gamma glutamyl transferase \>3 U/L\*ULN, glucose \<2.8 mmol/L, \>19.4 mmol/L, potassium\<3 mmol/L, \>6 mmol/L, sodium \<130 mmol/L, \>150 mmol/L,Urea \<130 mmol/L, erythrocytes \<0.8\*LLN \>1.2\*ULN, hematocrit \<0.8\*LLN, \>1.2\*ULN, hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN, leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN, platelets \<75(10\^9/L), \>600(10\^9/L).
| percentage of participants | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose | 0 | 0 | 0 |
Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure were measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C.
| percentage of participants | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| <35.6 C | 0 | 0 | 6.7 |
| >37.7 C | 4.8 | 0 | 0 |
The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec).
| percentage of participants | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| ECG Mean Heart Rate: <50 beats per minute | 0 | 0 | 6.7 |
| PR Interval: >=200 milliseconds | 10.5 | 20.0 | 13.3 |
| QRS Duration: <=80 milliseconds | 36.8 | 20.0 | 33.3 |
Treatment-emergent suicidal ideation (SI) or suicidal behavior (SB) compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
| Participants | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| SI-Wish to be Dead, Day -1 | 3 | 0 | 1 |
| SI-Wish to be Dead, Day 14 | 1 | 0 | 0 |
| SI-Wish to be Dead, Day 77 | 1 | 0 | 1 |
| SB-Non-suicidal Self-injurious Behaviour, Day 77 | — | 1 | 0 |
Collected over From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/21 (0%) | 0/21 (0%) | 12/21 (57.1%) |
| TAK-041 40 mg | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| TAK-041 160 mg | 0/15 (0%) | 0/15 (0%) | 8/15 (53.3%) |
| Event | Placebo | TAK-041 40 mg | TAK-041 160 mg |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/21 | 2/7 | 0/15 |
| HeadacheNervous system disorders | 2/21 | 1/7 | 1/15 |
| NasopharyngitisInfections and infestations | 3/21 | 1/7 | 0/15 |
| Back PainMusculoskeletal and connective tissue disorders | 0/21 | 1/7 | 1/15 |
| Lymphocyte Count DecreasedInvestigations | 0/21 | 1/7 | 0/15 |
| Procedural HeadacheInjury, poisoning and procedural complications | 0/21 | 1/7 | 0/15 |
| HypokalaemiaMetabolism and nutrition disorders | 0/21 | 1/7 | 0/15 |
| FatigueGeneral disorders | 2/21 | 0/7 | 1/15 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/21 | 0/7 | 0/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/21 | 0/7 | 0/15 |
All randomized participants.
| Age, Continuous(years) | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics | Total |
|---|---|---|---|---|---|
| Mean | 42.0 ± 16.5 | 39.3 ± 16.1 | 46.8 ± 12.1 | 43.4 ± 9.6 | 43.8 ± 12.1 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 2 | 2 | 6 |
| Male | 3 | 2 | 7 | 5 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 9 | 7 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 4 | 6 | 16 |
| White | 0 | 1 | 4 | 0 | 5 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2017 to primary completion in Sep 2019, 20 months.
Results were first posted in Feb 2021, 1 year 4 months after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 20 months is close to that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-041